NAMS

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.15
Percentage change 0.64	%

Peers: JNJ PFE MRK BMY LLY GILD AMGN REGN VRTX BIIB

| Held by: IBB DWAS SBIO FYC FYX ONEQ GWX FHLC SMMV FAD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	43.32%	Shs Outstand	92.17M	Perf Week	-3.58%
Market Cap	2.53B	Forward P/E	-	EPS next Y	-1.81	Insider Trans	-2.56%	Shs Float	60.55M	Perf Month	-10.94%
Income	-	PEG	-	EPS next Q	-0.49	Inst Own	35.60%	Short Float	4.90%	Perf Quarter	24.54%
Sales	-	P/S	-	EPS this Y	5.52%	Inst Trans	8.58%	Short Ratio	3.63	Perf Half Y	25.40%
Book/sh	4.11	P/B	5.77	EPS next Y	10.83%	ROA	-	Short Interest	2.97M	Perf Year	34.66%
Cash/sh	3.96	P/C	5.99	EPS next 5Y	-	ROE	-	52W Range	15.19 - 27.29	Perf YTD	-7.78%
Dividend Est.	0.08 (0.33%)	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-13.16%	Beta	-0.04
Dividend TTM	-	Quick Ratio	10.61	Sales past 5Y	-28.76%	Gross Margin	-	52W Low	56.02%	ATR (14)	1.16
Dividend Ex-Date	-	Current Ratio	10.61	EPS Y/Y TTM	-210.57%	Oper. Margin	-	RSI (14)	45.45	Volatility	4.39% 4.21%
Employees	29	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	44.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-165.81%	Payout	-	Rel Volume	1.15	Prev Close	23.55
Sales Surprise	1455.07%	EPS Surprise	63.94%	Sales Q/Q	-	Earnings	Nov 06 BMO	Avg Volume	816.48K	Price	23.70
SMA20	-5.79%	SMA50	0.57%	SMA200	19.61%	Trades		Volume	935,516	Change	0.64%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-30-24	Initiated	H.C. Wainwright	Buy	$48
May-15-24	Initiated	TD Cowen	Buy
Mar-14-24	Initiated	Scotiabank	Sector Outperform	$35
Jan-18-24	Initiated	Guggenheim	Buy	$30
Jan-16-24	Initiated	Piper Sandler	Overweight	$37
Oct-30-23	Initiated	RBC Capital Mkts	Outperform	$25

Jan-10-25 08:00AM	NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities (GlobeNewswire)
Jan-09-25 03:38PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-13-24 05:16PM	NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-11-24 09:37PM	NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
03:06PM	NewAmsterdam Pharma Stock Hits 90-Plus RS Rating (Investor's Business Daily)
05:10PM	Loading…
Dec-10-24 05:10PM	NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug (Investor's Business Daily) +41.41%
04:34PM	NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
07:00AM	NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (GlobeNewswire)
Dec-06-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-21-24 07:37AM	NewAmsterdam Pharma Reports Promising Phase 3 Trial Results (TipRanks)
Nov-20-24 04:13PM	NewAmsterdam Dives And Sacrifices A Cup Base Despite A Winning Cholesterol Study (Investor's Business Daily) -15.50%
07:00AM	NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH (GlobeNewswire)
Nov-18-24 03:20PM	NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 (GlobeNewswire)
Nov-06-24 08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results (GlobeNewswire) +13.73%
Nov-01-24 05:26PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:30PM	Loading…
Oct-28-24 04:30PM	NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November (GlobeNewswire)
Oct-04-24 04:30PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-06-24 04:32PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-30-24 08:00AM	NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-07-24 08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results (GlobeNewswire)
Aug-02-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.35%
Jul-29-24 08:54AM	NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations (Investor's Business Daily) -8.54%
08:00AM	NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia (GlobeNewswire)
Jul-26-24 04:01PM	NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024 (GlobeNewswire)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire)
Jul-08-24 08:00AM	NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors (GlobeNewswire)
Jul-03-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-11-24 08:00AM	NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office (GlobeNewswire)
Jun-07-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-24 08:00AM	NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June (GlobeNewswire)
08:00AM	Loading…
May-21-24 08:00AM	NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings (GlobeNewswire)
May-09-24 08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results (GlobeNewswire)
May-03-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-24 08:00AM	NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024 (GlobeNewswire)
Apr-09-24 08:00AM	NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease (GlobeNewswire)
Apr-01-24 08:00AM	NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer (GlobeNewswire) -9.64%
Mar-25-24 08:00AM	NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress (GlobeNewswire)
Mar-13-24 01:32PM	NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up (Zacks)
Mar-12-24 08:00AM	NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD (GlobeNewswire) +11.89%
Feb-28-24 08:33AM	NewAmsterdam Pharma Co NV (NAMS) Faces Net Loss in 2023 Despite Clinical Progress (GuruFocus.com)
08:00AM	NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-26-24 08:00AM	NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March (GlobeNewswire)
Feb-13-24 10:40PM	NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
04:01PM	NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
Feb-01-24 04:01PM	NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire) -6.01%
Jan-08-24 08:00AM	NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors (GlobeNewswire)
Jan-04-24 08:00AM	NewAmsterdam Pharma Announces 2024 Strategic Priorities (GlobeNewswire)
Nov-13-23 09:55AM	Forbion co-leads 129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023 (GlobeNewswire) -6.91%
08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights (GlobeNewswire)
Oct-31-23 12:05PM	RBC initiates coverage of NewAmsterdam on CETP inhibitor (Yahoo Finance Video) +25.52%
Oct-30-23 09:43AM	AbbVie upgraded, Cisco downgraded: Wall Street's top analyst calls (The Fly) +7.01%
Oct-23-23 08:00AM	NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer (GlobeNewswire) -10.07%
Oct-17-23 03:00AM	Tessellate BIO Emerges from Stealth (GlobeNewswire)
Sep-21-23 07:00AM	NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimers Disease Who Carry an ApoE4 Mutation (GlobeNewswire)
Sep-20-23 08:00AM	NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Aug-14-23 04:01PM	NewAmsterdam Pharma Announces Appointment of William BJ Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer (GlobeNewswire)
Aug-10-23 06:01AM	NewAmsterdam Pharma First Half 2023 Earnings: 0.92 loss per share (vs 1.50 profit in 1H 2022) (Simply Wall St.)
Aug-07-23 07:15AM	NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights (GlobeNewswire)
Jul-25-23 04:01PM	NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease (GlobeNewswire)
Jun-09-23 04:01PM	NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares (GlobeNewswire)
Jun-06-23 11:25PM	NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares (GlobeNewswire) -16.52%
04:01PM	NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares (GlobeNewswire)
Jun-05-23 07:00AM	NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients (GlobeNewswire)
Jun-03-23 12:15PM	NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023 (GlobeNewswire)
May-31-23 08:00AM	NewAmsterdam Pharma to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-23-23 08:00AM	NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023 (GlobeNewswire)
May-08-23 08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights (GlobeNewswire)

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
NAP PoolCo B.V.	Affiliate	Jan 10 '25	Proposed Sale	25.31	1,396,241	35,338,860		Jan 10 04:26 PM
ForGrowth NAP B.V.	10% Owner	Dec 30 '24	Sale	25.54	29,846	762,174	10,656,172	Jan 02 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 27 '24	Sale	25.95	41,472	1,076,290	10,686,018	Dec 30 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 26 '24	Sale	26.01	33,438	869,629	10,727,490	Dec 30 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 20 '24	Sale	25.60	49,772	1,274,064	10,802,224	Dec 26 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 23 '24	Sale	25.49	25,132	640,625	10,777,092	Dec 26 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 24 '24	Sale	25.66	16,164	414,831	10,760,928	Dec 26 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 18 '24	Sale	26.10	100,728	2,628,907	10,908,502	Dec 20 04:25 PM
ForGrowth NAP B.V.	10% Owner	Dec 19 '24	Sale	25.45	56,506	1,437,806	10,851,996	Dec 20 04:25 PM
ForGrowth NAP B.V.	10% Owner	Dec 17 '24	Sale	25.95	114,384	2,968,756	11,009,230	Dec 18 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 16 '24	Sale	25.00	1,096	27,400	11,123,614	Dec 18 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 12 '24	Sale	25.39	166,011	4,215,827	11,150,461	Dec 16 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 13 '24	Sale	25.01	25,751	644,048	11,124,710	Dec 16 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 10 '24	Sale	25.37	308,250	7,818,808	11,470,510	Dec 12 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 11 '24	Sale	25.46	154,038	3,921,809	11,316,472	Dec 12 04:15 PM
ForGrowth NAP B.V.	10% Owner	Nov 18 '24	Sale	25.08	33,273	834,440	11,778,760	Nov 19 04:15 PM
ForGrowth NAP B.V.	10% Owner	Nov 15 '24	Sale	25.02	8,530	213,436	11,812,033	Nov 19 04:15 PM
ForGrowth NAP B.V.	10% Owner	Nov 14 '24	Sale	25.01	9,832	245,856	11,820,563	Nov 15 04:36 PM
ForGrowth NAP B.V.	10% Owner	Nov 13 '24	Sale	25.00	1,066	26,655	11,830,395	Nov 15 04:36 PM
NAP PoolCo B.V.	Affiliate	Nov 13 '24	Proposed Sale	24.98	1,553,759	38,812,900		Nov 13 04:23 PM
Kooij Louise Frederika	Chief Accounting Officer	Oct 01 '24	Sale	15.72	45,000	707,400	0	Oct 01 05:23 PM
Kooij Louise Frederika	Officer	Oct 01 '24	Proposed Sale	17.29	45,000	778,050		Oct 01 05:12 PM
Audet Juliette Berangere	Chief Business Officer	Sep 26 '24	Buy	15.70	1,104	17,333	1,104	Sep 30 05:22 PM
Davidson Michael H.	Chief Executive Officer	Aug 20 '24	Buy	16.27	5,000	81,350	209,784	Aug 22 04:30 PM
Davidson Michael H.	Chief Executive Officer	Jun 20 '24	Buy	17.26	5,000	86,308	204,784	Jun 24 08:30 AM
Topper James N	Director	Mar 26 '24	Buy	21.50	8,429	181,224	3,008,429	Mar 28 04:30 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Mar 26 '24	Sale	21.50	190,476	4,095,234	0	Mar 27 04:30 PM
LANGE LOUIS G	Director	Feb 13 '24	Buy	19.00	5,000	95,000	24,878	Feb 21 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NewAmsterdam Pharma Company NV

Upgrade your FINVIZ experience